![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260924_Merck_Therapeutic_Indications-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Merck<\/p>\n Event Type<\/strong><\/p>\n Clinical Trial Data Readout<\/p>\n Modality<\/strong><\/p>\n Tetravalent Tri-Specific Antibody (Wnt Pathway Agonist)<\/p>\n Asset<\/strong><\/p>\n Remigromig (EYE103)<\/p>\n Target<\/strong><\/p>\n Wnt Signaling \/ Blood-Retinal Barrier<\/p>\n Disease Area<\/strong><\/p>\n Diabetic Macular Edema<\/p>\n Both remigromig doses met the Week 52 noninferiority endpoint versus ranibizumab for change in best-corrected visual acuity in the 984-participant BRUNELLO trial. Merck also disclosed higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and treatment discontinuation due to adverse events in the remigromig groups. Numerical efficacy, noninferiority margins and safety rates remain unavailable.<\/p>\n BRUNELLO randomized adults with diabetic macular edema 1:1:1 to 0.5 mg remigromig, 0.8 mg remigromig or 0.5 mg ranibizumab every four weeks for one year. Remigromig is a tetravalent tri-specific antibody designed to activate Wnt signaling and repair the blood-retinal barrier rather than directly inhibit VEGF.<\/p>\n The second study year introduces personalized treatment intervals, making durability and injection burden key future measures. A second pivotal DME trial is ongoing. The safety imbalance is clinically consequential because the disclosed events can threaten vision; the absence of numbers prevents assessment of severity, timing, dose response and causal relationship.<\/p>\n Interpretation one is that restoring vascular-barrier signaling can achieve anti-VEGF-comparable vision outcomes through a new mechanism. Replication in two doses supports biological activity. Against it, noninferiority may coexist with small absolute gains, similar injection burden or unfavorable anatomy, and the numerical margin is undisclosed.<\/p>\n Interpretation two is that the safety signal could reflect disease progression, Wnt-pathway biology, ascertainment or chance. The presence of higher PDR, hemorrhage and discontinuation rates across treatment arms makes a drug-related effect plausible but not established. Detailed event counts, baseline retinopathy balance, central adjudication and the independent BAROLO result could upgrade or falsify either explanation. A durable benefit with reduced treatment frequency and no reproducible safety imbalance would strengthen the program; confirmed excess vision-threatening events would materially weaken benefit-risk.<\/p>\n Merck acquired EyeBio and remigromig, formerly EYE103, through a 2024 transaction. Diabetic macular edema results from breakdown of the retinal vascular barrier and fluid accumulation in the macula. Standard intravitreal therapy suppresses VEGF; remigromig instead seeks to activate Wnt signaling involved in vascular integrity.<\/p>\n The pivotal efficacy result is positive, but the overall signal is mixed because the same disclosure identifies potentially vision-threatening imbalances. No directional claim stronger than “endpoint met with unresolved safety risk” is justified until complete data and replication are available.<\/p>\n Signal Importance: 5 of 5. Signal Direction: mixed. Confidence in Facts: high for the randomized design and qualitative topline result. Confidence in Interpretation: moderate-low until numerical efficacy and adverse-event data are presented.<\/p>\n","protected":false},"excerpt":{"rendered":" Both remigromig doses met the Week 52 noninferiority endpoint versus ranibizumab for change in best-corrected visual acuity in the 984-participant BRUNELLO trial. Merck also disclosed higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and…<\/p>\n","protected":false},"author":1,"featured_media":3439,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[865,123,864],"class_list":["post-3434","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-diabetic-macular-edema","tag-merck","tag-remigromig"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3434"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3434\/revisions"}],"predecessor-version":[{"id":3452,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3434\/revisions\/3452"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3439"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n